STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
about
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
STA-8666, a novel HSP90 inhibi ...... e models of pediatric sarcoma.
@en
STA-8666, a novel HSP90 inhibi ...... e models of pediatric sarcoma.
@nl
type
label
STA-8666, a novel HSP90 inhibi ...... e models of pediatric sarcoma.
@en
STA-8666, a novel HSP90 inhibi ...... e models of pediatric sarcoma.
@nl
prefLabel
STA-8666, a novel HSP90 inhibi ...... e models of pediatric sarcoma.
@en
STA-8666, a novel HSP90 inhibi ...... e models of pediatric sarcoma.
@nl
P2093
P2860
P356
P1433
P1476
STA-8666, a novel HSP90 inhibi ...... e models of pediatric sarcoma.
@en
P2093
Arnulfo Mendoza
Christine M Heske
David A Proia
Jane Trepel
Joshua T Baumgart
Leah D Edessa
Lee J Helman
Len Neckers
Sunmin Lee
P2860
P304
65540-65552
P356
10.18632/ONCOTARGET.11869
P407
P577
2016-09-06T00:00:00Z